MARKET

FULC

FULC

Fulcrum
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.41
+0.21
+1.15%
Closed 16:00 05/22 EDT
OPEN
18.25
PREV CLOSE
18.20
HIGH
19.51
LOW
17.21
VOLUME
65.91K
TURNOVER
--
52 WEEK HIGH
22.96
52 WEEK LOW
4.370
MARKET CAP
430.12M
P/E (TTM)
-6.1214
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 4 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average FULC stock price target is 25.25 with a high estimate of 29.00 and a low estimate of 19.00.

EPS

FULC News

More
Fulcrum Therapeutics Announces Multiple Presentations at the 2020 American Academy of Neurology (AAN) Science Highlights Virtual Platform
GlobeNewswire · 4d ago
Fulcrum Therapeutics Reports Multiples Presentations At American Academy of Neurology Science Highlights Virtual Platform
Fulcrum Therapeutics, Inc. (NASDAQ:FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced multiple presentations at the
Benzinga · 4d ago
Fulcrum Therapeutics, Inc. (FULC) Shares March Higher, Can It Continue?
As of late, it has definitely been a great time to be an investor in Fulcrum Therapeutics, Inc. (FULC).
Zacks · 05/14 13:42
75 Biggest Movers From Yesterday
Gainers SIFCO Industries, Inc. (NYSE: SIF) shares climbed 88% to close at $4.14 on Wednesday following Q2 results. Sifco Industries posted Q2 earnings of $0.57 per share, versus a year-ago loss of $0.43 per share.
Benzinga · 05/14 08:26
Fulcrum Therapeutics, Inc. (FULC) Q1 2020 Earnings Call Transcript
With me on today's call are Robert Gould, president and chief executive officer; Diego Cadavid, senior vice president of clinical development; Owen Wallace, chief scientific officer; and Bryan Stuart, chief operating officer. Let me quickly run through this m
Motley Fool · 05/14 01:31
Fulcrum Therapeutics, Inc. (FULC) CEO Robert Gould on Q1 2020 Results - Earnings Call Transcript
Seeking Alpha - Transcript · 05/13 17:15
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers SIFCO Industries, Inc. (NYSE: SIF) shares jumped 117% to $4.7799 following Q2 results. Sifco Industries posted Q2 earnings of $0.57 per share, versus a year-ago loss of $0.43 per share.
Benzinga · 05/13 16:41
50 Stocks Moving In Wednesday's Mid-Day Session
Gainers SIFCO Industries, Inc. (NYSE: SIF) shares jumped 117% to $4.7799 following Q2 results. Sifco Industries posted Q2 earnings of $0.57 per share, versus a year-ago loss of $0.43 per share.
Benzinga · 05/13 16:41

Industry

Biotechnology & Medical Research
+1.01%
Pharmaceuticals & Medical Research
+0.05%

Hot Stocks

Symbol
Price
%Change

About FULC

Fulcrum Therapeutics, Inc. is a United States-based clinical-stage biopharmaceutical company. The Company focuses on improving the lives of patients with genetically defined rare diseases. The Company have developed a product engine which identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. The Company is also engaged in developing drugs for the treatment for the root cause of muscle disorders, central nervous system disorders and blood disorders.
More

Webull offers kinds of Fulcrum Therapeutics Inc stock information, including NASDAQ:FULC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FULC stock news, and many more online research tools to help you make informed decisions.